Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
Nicholas A. Marston, Erin A. Bohula, Ajay Bhatia, Gaetano M. De Ferrari et autres
19 citationsJAMA
Bart Wollaert
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
14Publications signalées
838Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Lipoproteins and Cardiovascular HealthAtrial Fibrillation Management and OutcomesDiabetes, Cardiovascular Risks, and LipoproteinsVenous Thromboembolism Diagnosis and ManagementProtease and Inhibitor Mechanisms
Publications récentes
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
Philippe Gabríel Steg, Michael Szarek, J. Wouter Jukema, Deepak L. Bhatt et autres
25 citationsCirculation
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Shaun G. Goodman, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres
24 citationsEuropean Heart Journal - Cardiovascular Pharmacotherapy
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide
Sylvia Haas, A. John Camm, Harald Darius, Jan Steffel et autres
12 citationsClinical Research in Cardiology
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Emil Hagström, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres
125 citationsCirculation
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo, Garen Manvelian et autres
144 citationsJournal of the American College of Cardiology
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Gregory G. Schwartz, Michael Szarek, Vera Bittner, Deepak L. Bhatt et autres
40 citationsDiabetes Care
Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
Jaap Seelig, Martin E W Hemels, Olivier Xhaët, Maarten C.M. Bongaerts et autres
5 citationsJournal of Thrombosis and Haemostasis
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie T. Baccara‐Dinet et autres
331 citationsThe Lancet Diabetes & Endocrinology
Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
Shinya Goto, Pantep Angchaisuksiri, Jean‐Pierre Bassand, A. John Camm et autres
55 citationsJournal of the American Heart Association
Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry
Frank Cools, Bart Wollaert, Geert Vervoort, Stefan Verstraete et autres
20 citationsActa cardiologica. Supplementum
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry
Jitendra PS. Sawhney, V A Kothiwale, Vikas Bisne, Rajashekhar Durgaprasad et autres
21 citationsIndian Heart Journal
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.